
    
      The study was conducted as an open label, balanced, randomised, two-treatment, two-period,
      two-sequence, single-dose, crossover , bioequivalence study on glimepiride comparing
      glimepiride 1mg tablets of Ranbaxy laboratories limited with Amaryl 1mg tablets of in
      healthy, adult, human, subjects under fed conditions.

      Thirty-two (32) subjects were recruited for this study and all subjects were healthy adults.
      Thirty-two (32) subjects began the study, and thirty-two (32) completed the clinical portion
      of the study.
    
  